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Abstract
Host innate and adaptive immune responses must be tightly regulated by an intricate balance 
between positive and negative signals to ensure their appropriate onset and termination while 
fighting pathogens and avoiding autoimmunity; persistent pathogens may usurp these regulatory 
machineries to dampen host immune responses for their persistence in vivo. Here we demonstrate 
that miR146a is up-regulated in monocytes from hepatitis C virus (HCV)-infected individuals 
compared to control subjects. Interestingly, miR146a expression in monocytes without HCV 
infection increased, whereas its level in monocytes with HCV infection decreased, following Toll-
like receptor (TLR) stimulation. This miR146a induction by HCV infection and differential 
response to TLR stimulation were recapitulated in vitro in monocytes co-cultured with hepatocytes 
with or without HCV infection. Importantly, inhibition of miR146a in monocytes from HCV-
infected patients led to a decrease in IL-23, IL-10, and TGF-β expressions through induction of 
suppressor of cytokine signaling 1 (SOCS1) and inhibition of signal transducer and activator 
transcription 3 (STAT3), and this subsequently resulted in a decrease in regulatory T cells (Tregs) 
accumulated during HCV infection. These results suggest that miR146a may regulate SOCS1/
STAT3 and cytokine signaling in monocytes, directing T cell differentiation and balancing immune 
clearance and immune injury during chronic viral infection.
Keywords
HCV; miR146a; monocytes; regulatory T cells; SOCS1; STAT3
#Corresponding author: Zhi Q. Yao, M.D., Ph.D., Professor of Medicine, Infectious Diseases, Director, Center of Excellence for HIV/




J Viral Hepat. Author manuscript; available in PMC 2017 October 01.
Published in final edited form as:














Host innate and adaptive immune responses must be tightly regulated by an intricate balance 
between positive and negative signals to ensure their appropriate onset and termination while 
fighting pathogens and avoiding autoimmunity; persistent pathogens may usurp these 
regulatory machineries to dampen host immune responses for their persistence in vivo. 
Hepatitis C virus (HCV), a blood-borne viral infection characterized by a high rate of 
chronic infection, has evolved multiple strategies to evade host immune responses, thus 
becoming an excellent model to study the mechanisms of persistent viral infections [1–2]. 
While the use of direct antiviral agents (DAA) has resulted in a significant improvement in 
the outcome of HCV treatment, this therapeutic cocktail is still under development and 
already facing new issues such as viral mutation, relapse, and re-infection following therapy 
[3–4]. Additionally, the lack of a vaccine for this virus is a major hurdle to control this 
global infection. The failure to successfully manage this chronic viral infection and to 
develop an effective vaccine stems from our incomplete understanding of HCV-host 
interactions that lead to viral persistence.
While a high rate of genetic variability in HCV structural and non-structural proteins 
(quasispecies) may facilitate viral persistence, HCV-elicited immune responses appear to be 
too weak to resolve infection in most humans or to protect against re-infection in 
chimpanzees [5–6]. It appears that virus-mediated impairment of innate and adaptive 
immune response is a major mechanism by which persistent infection is established [1–2]. 
We have previously shown that chronically HCV-infected individuals exhibit an aberrant 
secretion of IL-23 and IL-10 by monocytes, contributing to the differentiation of Th17 cells 
and accumulation of Foxp3+ regulatory T cells (T-regs) [7–10]. However, the precise 
mechanisms that control IL-23 and IL-10 expression in monocytes and T cell differentiation 
remain elusive. Notably, aberrant inflammatory activities may also contribute towards 
immune-mediated injury [11–12]. Therefore, additional studies are required to understand 
how these immune cells are fine-tuned in host defense and immune injury during chronic 
viral infections.
microRNAs (miRNAs or miRs) are a class of small, non-coding RNAs that can regulate 
gene expression through translational repression or target mRNA degradation and have been 
implicated as negative regulators of innate and adaptive immune responses [13–15]. 
Genome-wide expression profiling of miRNAs in human monocytes has revealed several 
endotoxin-responsive miRNAs (miR146a/b, miR155, miR132, and miR125b) that can 
regulate inflammatory processes at multiple levels [16]. miR146a has been identified as a 
key modulator of differentiation and function of cells in both innate and adaptive immunity 
[17–19]. Recent studies using miR146a-deficient mice have reported that miR146a acts as a 
brake, attenuating the innate immune response by inhibiting signaling pathways, including 
Toll-like receptor (TLR), and RIG-I-like receptor (RLR) pathways [20–22]. In human 
monocytes, miR146a is induced by LPS stimulation in a NF-κB-dependent manner and 
inhibits the innate immune responses by targeting TNF receptor-associated factor 6 
(TRAF6) and IL-1 receptor associated kinase 1 (IRAK1) genes [16]. In chronically HCV-
infected individuals, miR146a has been shown to be up-regulated as a feedback mechanism 
to prevent an over-stimulated inflammatory state [23–27]. However, the precise mechanism 
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for miR146a induction in monocytes and its role in regulation of T cell differentiation during 
HCV infection remain to be elucidated.
In this study, we demonstrated an increase of miR146a expression in monocytes from 
chronically HCV-infected individuals, and in monocytes incubated with HCV-infected 
hepatocytes, with or without TLR stimulation. We also investigated the role of HCV-induced 
miR146a expression in monocytes in regulating T cell differentiation and the potential 
mechanism involved in regulating inflammatory cytokines leading to viral persistence.
Materials and Methods
Subjects
The study protocol was approved by the institutional review board of East Tennessee State 
University and James H. Quillen VA Medical Center (ETSU/VA IRB, Johnson City, TN), 
which has contributed to a database for the storage of blood samples from HCV-infected 
individuals for the purpose of viral immunology studies. The study subjects comprised three 
populations: 1) 42 chronically HCV-infected patients, HCV genotype (70% type 1, 30% type 
2 or 3) and viral load (ranging from 12,300 ~ 50,000,000 IU/ml) were performed by 
Lexington VAMC, and all subjects were virologically and serologically positive for HCV 
prior to the antiviral treatment; 2) 5 HCV subjects who achieved SVR following antiviral 
therapy with pegylated interferon plus ribavirin and boceprevir; and 3) 22 healthy subjects 
(HS, blood buffy coat derived from Key Biologics LLC. Memphis, TN) who were negative 
for HBV, HCV, and HIV infection. Written informed consent was obtained from all 
participants. The majority of the study subjects were male. The mean age of the three 
populations was comparable (P>0.05).
Cell isolation and culture
Human peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Percoll 
gradients (GE Heathcare, Piscataway, NJ). CD14+ monocytes were further purified from 
PBMCs using anti-CD14 magnetic beads according to the manufacturer’s instructions 
(Miltenyi Biotec, Auburn, CA). The cells were cultured in RPMI 1640 medium containing 
10% FBS (Atlanta Biologicals, Flowery Branch, GA), 100 IU/ml penicillin and 100 μg/ml 
streptomycin and 2 mM L-glutamine (Thermo Scientific, Logan, Utah) at 37°C and 5% CO2 
atmosphere. In some experiments, cells were incubated with or without 1 μg/ml LPS and 2.5 
μg/ml R848 (Santa Cruz Biotechnology, Santa Cruz, CA) for 6h. RNA was then isolated and 
used for PCR analysis.
Co-culture of healthy CD14+ monocytes with HCV+/− Huh-7 hepatocyte
Transfection of Huh-7 hepatocytes (kindly provided by Dr. T.J.Liang, Liver Section, NIH/
NIDDK) with HCV JFH-1 strain (kindly provided by Dr. T. Wakita) was carried out as 
described previously [28–29]. For the co-culture experiments, HCV+/− Huh-7 hepatocytes 
were serum-starved for 18h and then activated with rhIFN-γ (0.1μg/ml, R&D Systems) for 
48 h to boost the HCV replication [28–29]. Activated hepatocytes were recovered by 0.05% 
trypsin-EDTA, and then plated at 5 × 105 cells/well in a 12-well plate. Purified healthy 
CD14+ monocytes were added to the adherent hepatocytes in RPMI media, incubated for 
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different times, then stimulated with LPS/R848 for 6h, and RNA was isolated and analyzed 
by RT-PCR.
Measurement of miRNA levels by Real-time RT-PCR
Total RNAs were isolated from monocytes using RNAzol (Molecular Research Center, Inc, 
Cincinnati, OH) according to the manufacturer’s protocol. miRNA levels were quantified by 
real-time RT-PCR using specific miRNA assay primer sets and TaqMan Universal Master 
Mix (both from Applied Biosystems). Specific primers for miR146a, miR155-5p, and U6 
small nucleolar RNA (snRU6) were obtained from Applied Biosystems. Real-time RT-PCR 
was performed using a 4800 PCR machine (Bio-Rad System) and miR146a/miR155 values, 
normalized to snRU6 levels, are expressed as either relative amounts or fold changes using 
the 2−Δct or 2−ΔΔct quantification method.
Monocyte transfections
The CD14+ monocytes from HCV patients and HS were transfected with 30 pmol of 
miR146a inhibitor or the anti-miR negative control (Life technologies, Grand Island, NY) 
using the Human Monocyte Nucleofector Kit and Nucleofector I Device (Lonza, Allendale, 
NJ). Transfection efficiency was approximately 60% for primary monocytes (50% in naïve 
CD4+ T cells and 20% in nature killer cells) as determined by the transfection of a 
fluorescently-labeled negative miRNA control. After transfection, monocytes were cultured 
in IMEM medium (Lonza, Allendale, NJ) supplemented with 10% FBS, 100 ng/ml IL-4 
(Peprotech, Rocky Hill, NJ) and 75 ng/ml GM-CSF (Peprotech) for 24–48 h. The monocytes 
were stimulated with LPS/R848 for 6 h prior to harvest. The supernatants and cell pellets 
were harvested for cytokine measurement and Western blot analysis, respectively.
Cytokine measurements
IL-23, IL-10, TGF-β1, IL-12, IFN-α and IFN-β productions were measured in the culture 
supernatants of HCV patient as well as HS monocytes that were treated with miR146a 
inhibitor or negative control, using commercially available ELISA kits (R&D, Minneapolis, 
MN) according to manufacturer’s instructions.
Western blot analysis
The transfected monocytes from HCV-infected individuals and HS were lysed on ice in 
RIPA lysis buffer (Boston BioProducts Inc, Ashland, MA) in the presence of protease 
inhibitors (Thermo Scientific, Rockford, IL). Cell lysates were centrifuged for 10 min at 
4°C, supernatants were recovered and the protein concentrations were measured by Pierce 
BCA protein assay kit (Thermo Scientific, Rockford, IL). Proteins were separated by SDS-
PAGE, and transferred to polyvinylidene difluoride membranes. Membranes were blocked 
with 5% milk, 0.5% Tween-20 in Tris buffered saline (TBS), and incubated with the 
appropriate primary antibodies according to the manufacturer’s instruction (anti-SOCS1: 
Millipore, Temecula, CA; anti-phosphorylated STAT3 and anti-phosporylated STAT1: Cell 
Signaling Technology, Inc, Danvers, MA). Appropriate horseradish peroxide-conjugated 
secondary antibody (Cell Signaling) was then used and proteins were detected using 
enhanced chemiluminescence assay kit (Amersham, Piscataway, NJ). Membranes were 
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stripped and re-probed with anti-β-actin antibody as an internal control (Sigma-Aldrich, St. 
Louis, MO). Protein bands were captured and quantitatively analyzed by Chemi DocTM MP 
Imaging System (Bio-Rad System).
Co-culture of CD14+ monocytes interfering miR146a with CD14- PBMCs from HCV-infected 
individuals
CD14+ monocytes isolated from HCV-infected individuals and HS were transfected with 
miR146a inhibitor or anti-miR negative control and then cultured in IMEM medium (Lonza, 
Allendale, NJ) supplemented with 10% FBS, 100 ng/ml IL-4 (Peprotech, Rocky Hill, NJ) 
and 75 ng/ml GM-CSF (Peprotech), as described above. After 24 h, the transfected 
monocytes were co-cultured with autologous CD14− PBMCs in the presence of 50 ng/ml 
IL-2 (eBioscience, San Diego, CA) for 5 days, followed by stimulation with 100 ng/ml of 
PMA (InvivoGen, San Diego, CA) and 1 μg/ml ionomycin (Invitrogen) for 6 h, with 
brefeldin A (Biolegend, San Diego, CA), which was added 5 h prior to cell harvest to inhibit 
cytokine secretion. Cells were analyzed by flow cytometry for Th17 and T-reg cells.
Flow cytometry
Specific antibody direct conjugates was carried out using CD4-PE, CD4-APC and CD25-
Alexa488 for cell surface staining, followed by IL-17A-PE for intracellular staining or 
Foxp3-Pecy5 for transcription factor staining. All antibodies were purchased from 
eBioscience. IL-17A and Foxp3 staining were carried out using Inside Stain kit and FoxP3 
Staining Buffer Set (Miltenyi Biotec), respectively, according to the manufacturer’s 
instructions. The fluorescence minus one (FMO) strategy and isotype controls were used to 
adjust multicolor compensation for cell gating and determine background levels. The cells 
were collected on an Accuri C6TM flow cytometer (BD, Franklin Lakes, NJ) and analyzed 
using FlowJo software (Tree Star, Inc., Ashland, OR).
Statistical analysis
The data were expressed as mean ± SE or median with interquartile, depending on the 
characteristics of the data distribution. Comparisons between groups were made using one-
way analysis of variance (ANOVA). Independent t test or paired t test was used to compare 
the difference of mean between each two groups. Mann-Whitney test was used to compare 
the difference of median between each two groups. *P < 0.05 or **P < 0.01 were considered 
statistically significant or very significant.
Results
miR146a is up-regulated in monocytes from chronically HCV-infected individuals
Previous studies reported the up-regulation of miR146a in different immune cells from 
HCV-infected individuals [23–27]. To analyze the induction of miRNA146a in monocytes 
during HCV infection, we measured miR146a levels in CD14+ monocytes isolated from 
PBMCs of 12 chronically HCV-infected patients, 5 SVR individuals, and 4 HS, using real-
time PCR. As shown in Fig. 1A (left panel), miR146a expression in monocytes from HCV-
infected patients was up-regulated more than 3- to 6-fold compared to SVR and HS, 
respectively. Notably, miR146a levels were decreased in SVR subjects following antiviral 
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therapy, but were not completely restored to the levels seen in HS. Since miR146a 
expression is induced via TLR stimulation [16], we also observed its induction in monocytes 
stimulated with LPS and R848. Following TLR stimulation, miR146a levels were 2-fold 
higher in HCV patients than in HS, whereas no significant differences in its levels were 
observed between SVR and HS (Fig. 1A, right panel).
In order to illustrate the effect of LPS/R848 stimulation on miR146a expression in 
monocytes, we dynamically measured miR146a levels at various time points following TLR 
stimulation. Notably, miR146a expression in monocytes from HCV patients was 
significantly higher than HS with TLR stimulation (Fig. 1B). We also observed the trend of 
miR146a expression in monocytes with and without LPS/R848 stimulation in HCV patients, 
SVR, and HS, respectively. Interestingly, while the miR146a expression in monocytes from 
individuals without HCV infection increased upon LPS/R848 stimulation (Fig. 1C and 1D), 
which is consistent with the notion of miR146a being a LPS-responsive gene [16], its 
expression was significantly decreased in monocytes from chronically HCV-infected 
individuals following 6 h TLR stimulation (Fig. 1E), although these changes were not 
statistically significant. These findings suggest that miR146a is up-regulated in monocytes 
from patients with HCV infection and that their response to TLR stimulation is different 
from monocytes from individuals without HCV infection.
miR146a is up-regulated in monocytes co-cultured with hepatocytes expressing HCV
The increases in miR146a expression in monocytes during HCV infection might be 
secondary to inflammation stimulation rather than directly due to HCV exposure. To further 
demonstrate whether HCV plays a primary role in inducing miR146a expression, we 
performed co-culture experiments by incubating monocytes from 3 HS with HCV+ Huh7 
cells or HCV− Huh7 cells for various time points (6 h, 12 h, 24 h and 48 h) with or without 
LPS/R848 stimulation, followed by measuring miR146a expression. As shown in Fig. 2A 
and 2B, we found that miR146a expression in CD14+ monocytes co-cultured with HCV+ 
Huh7 cells was higher at all time points than in monocytes co-cultured with HCV− Huh7 
cells, regardless of TLR stimulation. Of note, significant differences were observed only at 6 
h and 24 h.
In addition, by comparing miR146a expressions in monocytes with and without TLR 
stimulation, we found that miR146a expression was increased in monocytes co-cultured with 
HCV− Huh7 cells with LPS/R848 stimulation compared to non-stimulated monocytes (Fig. 
2C). However, miR146a expression was decreased in monocytes co-cultured with HCV+ 
Huh7 cells following 6h LPS/R848 stimulation (Fig. 2D), although these changes were not 
statistically significant. These data are consistent with the results observed in the ex vivo 
studies by isolated cells from HCV patients and HS (Fig. 1), suggesting that HCV infection 
alters miR146a expression in monocytes in response to TLR stimulation.
miR146a blockade in CD14+ monocytes from HCV-infected individuals inhibits IL-23, IL-10 
and TGF-β1 production
Human monocytes are able to produce inflammatory cytokines (IL-12, IL-23, IL-10 and 
TGF-β1) in response to pathogenic infection [30], and miRNAs can regulate these 
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cytokines, thus directing the differentiation of T lymphocytes [31–32]. In HS, it has been 
reported that early activation of developing monocyte-derived dendritic cells (MoDCs) 
allowed only a transient pro-inflammatory cytokine production that was followed by the 
down-regulation of IL-12 secretion through miR146a/SOCS1/STAT3 feedback regulations 
[33]. In HCV infection, we have shown an aberrant secretion of IL-23 and IL-10 by 
monocytes, which contribute to the differentiation of Th17 cells and accumulation of Foxp3+ 
regulatory T cells (T-regs) by SOCS1/STAT3 signaling pathways [7–10]. To better 
understand the role of miR146a in human monocyte functions during chronic viral infection, 
we blocked miR146a using an anti-miR146a specific inhibitor and then measured IL-23, 
IL-10, TGF-β1, IL-12, IFN-α and IFN-β protein levels in the culture supernatants of treated 
CD14+ monocytes from HCV-infected patients and HS using ELISA. As shown in Fig.3, 
miR146a inhibition followed by LPS/R848 stimulation in CD14+ monocytes from HCV 
patients resulted in significant decreases in IL-23, IL-10, and TGF-β1 levels compared with 
cells transfected with negative control. However, these changes were not observed in CD14+ 
monocytes from HS with the same treatment. In addition, the levels of type I IFN-α and 
IFN-β were unmeasurable under these conditions (data not shown). These results suggest 
that miR146a positively regulates IL-23, IL-10 and TGF-β expressions by monocytes during 
HCV infection.
miR146a regulates monocyte function during HCV infection through inhibition of SOCS1 
and induction of STAT3
We have previously demonstrated that HCV core-induced differential regulation of T and B 
lymphocyte responses and inhibition of IL-12 expression in monocytes is mediated by 
regulation of JAK/STAT signaling through induction of SOCS1, which is a negative 
modulator of the JAK/STAT pathway [28–29, 34–36]. It is also reported that IL-12 
production by MoDCs from HS is feedback regulated by miR146a/SOCS1/STAT3 pathways 
[33]. To further assess whether HCV-induced miR146a controls IL-23, IL-10 and TGF-β1 
production in monocytes through regulating SOCS1/STAT pathways, we analyzed SOCS1, 
STAT1 and STAT3 expressions by Western blot following blockade of miR146a expression 
in monocytes isolated from HCV-infected individuals and HS. As shown in Fig. 4A, the 
expression of SOCS1 in monocytes from HCV patients, but not HS, was significantly 
increased after inhibiting miR146a, at both 24 h and 48 h post-transfection, when compared 
to those treated with the negative control (Fig. 4A and 4B). Meanwhile, STAT3 
phosphorylation in monocytes from HCV patients, but not HS, was significantly decreased 
by miR146a inhibition at 48 h post transfection (Fig. 4A and 4C), whereas STAT1 
phosphorylation was not significantly changed in treated monocytes from both HCV and HS 
(Fig. 4A and 4D). These data suggest that miR146a may counter-regulate SOCS1 expression 
and subsequently cease its inhibitory effect on STAT3, thus increasing IL-23, IL-10 and 
TGF-β1 productions during HCV infection.
miR146a up-regulation in monocytes expands regulatory T cells during HCV infection
We have previously shown that HCV can differentially regulate IL-12/IL-23/IL-10 
expressions in innate immune cells, a milieu prone to the CD4 T differentiation of TH17 
cells and Foxp3+ T-regs in acquired immune responses [7–10]. To determine whether the 
increases in IL-23/IL-10/TGF-β production in monocytes by miR146a drives the 
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differentiation of TH17 cells and generation of T-reg cells during HCV infection, CD14+ 
monocytes isolated from 14 chronically HCV-infected individuals and 6 HS were transfected 
with miR146a inhibitor or negative control, and then co-cultured with autologous CD14− 
PBMCs ex vivo for 5 days, followed by measuring CD4+ IL-17+ TH17 cells and 
CD4+CD25+Foxp3+ T-regs by flow cytometry. We did not observe any significant changes 
in TH17 cell frequencies after miR146a inhibition in monocytes co-cultured with T cell 
enriched compartment (data not shown). However, we observed a significant decrease in T-
reg cell frequencies in T cells co-cultured with HCV patients’ monocytes that were 
transfected with miR146a inhibitor, but not HS monocytes with the same treatment (Fig. 
5A). Taken together, these results suggest that HCV-mediated miR146a induction in 
monocytes promotes regulatory cytokine expression and T-reg cell development, likely 
through SOCS1 and STAT3 signaling pathway, which have been shown to be dysregulated 
during chronic viral infection and contribute to immune suppression and viral persistence 
[28–29, 34–36].
Discussion
Innate immunity is the first line of host defense, evolved to recognize pathogen-associated 
molecular patterns (PAMPs) by microorganisms [37]. PAMPs are recognized via cellular 
receptors (such as TLR, RLR) expressed in immune cells and induce a wide spectrum of 
cytokine gene expressions, which in turn initiate and shape the inflammatory and adaptive 
immune responses. Following TLR activation, the adaptor protein MyD88 and IRAK1/
TRAF6 are recruited into a signaling molecule complex, which activates the downstream 
NF-κB transcription factor and results in up-regulation of immune response genes [38], 
including type I IFN (IFN-α, IFN-β) and pro- and anti-inflammatory cytokines (IL-12, 
IL-23, IL-10, TGF-β) that play pivotal roles in eliminating the invading pathogens. On the 
other hand, TLRs are double-edged swords as aberrant activation of their signaling can be 
harmful, causing pathological manifestations of inflammatory or autoimmune disorders. 
Thus, host innate and adaptive immune responses must be tightly regulated by elaborate 
mechanisms to control their onset and termination. Alternatively, pathogens that develop 
persistent infection, such as HCV and HIV, have developed multi-layer strategies to evade or 
subvert the immune responses for their survival or persistence within the host cells. The 
mechanisms for this immune evasion have yet to be fully understood.
miRNAs are an important class of small (18–25 nt), non-coding RNAs that can regulate 
gene expression through translational repression or target mRNA degradation [13–15]. More 
than 700 miRNAs have been identified in humans; some of them are widely expressed while 
others exhibit only limited developmental stage-, tissue- or cell type- specific expression 
patterns, and many of these miRNAs are involved in diverse biological processes, such as 
cytokine expression and cell differentiation [39–41]. As an ever-evolving strategy, viruses 
may be able not only to modulate cellular miRNA levels but also to interfere with the overall 
miRNA biogenesis. In particular, miR146a has been shown to be up-regulated in the serum, 
PBMCs, splenic marginal zone lymphoma (SMZL), and intra-graft of liver transplantation in 
HCV-infected individuals [23–27]. Despite these observations, little is known regarding how 
miR146a is induced in monocytes and what role it may play in regulation of T cell 
differentiation during HCV infection.
Ren et al. Page 8













Our study demonstrates that miR146a up-regulation by HCV infection plays a pivotal role in 
regulating inflammatory cytokine production in monocytes, likely via targeting SOCS1 and 
STAT3 signaling molecules and, subsequently, affecting T-reg differentiation during chronic 
viral infection. It has been reported that NF-κB-dependent miR146a induction inhibits 
innate immune responses by targeting the signaling proteins IRAK1, IRAK2, and TRAF6 
[16, 42]. This may be a feedback mechanism whereby microbial components induce NF-κB 
activation through a MyD88-dependent pathway, resulting in the up-regulation of miR146a 
expression, which in turn reduces NF-κB activity by down-regulating IRAK1/2 and TRAF6 
proteins. It is noteworthy that in this scenario, the TRIF-dependent, anti-viral IFN pathway 
induced by TLR4 remains intact [16]. In our experimental system, the expression levels of 
type I IFN-α and IFN-β in monocytes isolated from chronically HCV-infected individuals 
remained undetectable after stimulation with LPS/R848 ex vivo, likely reflecting the 
immunosuppressed state of chronic HCV infection. However, the expression of the 
inflammatory cytokines IL-23, IL-10, and TGF-β and the frequencies of T-regs that have 
been shown to be elevated during chronic HCV infection [7–10] were significantly reduced 
after miR146a inhibition.
By means of computational miRNA target prediction algorithms, potential targets of 
miR146a other than IRAK1/2, IRF5, and TRAF6 have been identified [16]. Thus, miR146a, 
like many other miRNAs, may target a wide spectrum of genes that could be involved in 
regulation of multiple independent cell signaling processes, such as STAT family. We have 
previously shown that HCV inhibits immune responses by regulating SOCS1 and STAT 
expression [28–29, 34–36]. Here, we further demonstrated that HCV appears to regulate 
SOCS1 and STAT3 expression through a miR146a-mediated signaling mechanism. Notably, 
miR155 has been shown to be upregulated in HCV-infected cells, and miR155 is also known 
to regulate SOCS1 expression [43–50]. One question is whether miR146a may affect 
SOCS1 expression through regulating miR155 expression. To answer this question, we 
examined the miR155 levels in monocytes transfected with miR146a antagomirs or negative 
controls, and the data showed that miR155 was not affected by miR146a transfection (data 
not shown), suggesting that miR146a may alter the SOCS1 expression through other 
mechanisms, rather than via miR155. While our study does not identify SOCS1 or STAT3 as 
the direct target of miR146a, the present data suggest a role for miR146a in controlling 
inflammatory cytokine production by regulating SOCS1 and STAT3 expression in 
monocytes, likely through an indirect mechanism, thus directing T cell differentiation and 
balancing the immune clearance and immune injury during chronic viral infection.
Foxp3+ T-reg cells maintain immune homeostasis by limiting different types of 
inflammatory responses. It has been reported that miR146a is prevalently expressed in T-reg 
cells and critical for their suppressor function [19]. Previous studies showed that the 
deficiency of miR146a in T-reg cells resulted in a breakdown of immunological tolerance 
manifest as a fatal IFN γ-dependent, immune-mediated pathologic lesion in a variety of 
organs, likely due to augmented phosphorylation of STAT1 [19]. Likewise, heightened 
STAT1 activation following selective ablation of SOCS1 was associated with similar T-reg-
mediated control of Th1 responses and autoimmune pathology [19]. Our results indicate that 
the differentiation of suppressor T-reg cells is controlled by the same single miRNA, 
miR146a, which is expressed in monocytes and induced by chronic viral infection through 
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the SOCS1/STAT3-mediated regulatory cytokines (IL-23/IL-10/TGF-β). Thus, our findings 
suggest that over-expression of miR146a in innate immunity cells can ensure T-reg cell 
development by maintaining an optimal threshold of cytokine receptor-dependent activation 
of transcription factors crucial for a particular type of immune response; in the case of 
chronic HCV infection, there is a Th2-type response, immune tolerance, and thus viral 
persistence. Based on our findings for miR146a in chronic HCV infection and other reports 
in HS, we propose a model (Fig. 5B) for HCV-induced, NF-κB-mediated miR146a 
induction in regulating cytokine production and T-regs development. HCV infection induces 
NF-κB activation and miR146a expression, which drives inflammatory cytokine (IL-23, 
IL-10, TGF-β) production by monocytes and subsequently prompts Foxp3+ T-reg 
differentiation. miR146a may also regulate TLR and cytokine signaling through a negative 
feedback loop involving SOCS1 and STAT3 pathway during chronic viral infection.
Notably, miR146a expression and regulation in monocytes from HCV-infected and 
uninfected individuals respond differently to TLR stimulation, in that miR146a levels were 
decreased and positively regulated cytokine productions by monocytes in HCV-infected 
patients; whereas miR146a levels increased and played a negative role in uninfected 
individuals [33] following TLR stimulation. This may have resulted from a paradoxical 
feedback regulatory effect of HCV and TLR on miR146a expression. While HCV or LPS 
alone can induce miR146a expression, they also trigger the expression of RNA 
exoribonuclease (such as ERI1) that binds to the 3’ end of histone mRNAs and degrades 
them. We have previously shown HCV delivers negative signaling to NF-κB as well as AP-1 
pathways, and we have recently found that ERI1 is significantly up-regulated in monocytes 
from HCV-infected individuals following TLR stimulation (data not shown). Therefore, 
over-activation of monocytes by both HCV and TLR stimulations may lead to triggering of 
ERI1 feedback mechanisms for immune homeostasis, perhaps explaining the differential 
expression and regulatory effect of miR146a in monocytes we observed in HCV-infected 
versus uninfected individuals in response to TLR stimulation. Another possibility is that the 
different levels of miR146a and its response to TLR stimulation might be related to the 
monocyte subset (classical, intermediate, non-classical monocytes, or M1 vs M2 monocyte) 
alterations in HCV-infected individual vs HS, which is an interesting question that need to 
be addressed in future studies.
In this study, we suggest that excessive activation of STAT3 is kept in check by SOCS1, 
which is double-checked by miR146a to ensure appropriate immune responses in vivo. It 
may be that HCV-mediated up-regulation of miR146a fine-tunes the TLR and cytokine 
signaling pathways rather than totally blocking these signals. Nevertheless, the counter-
regulatory effects of miR146a on TLR and cytokine signaling may balance immune 
signaling, fine-tuning immune-mediated viral clearance and host injury. Therefore, we 
conclude that miR146a may regulate SOCS1/STAT3 signaling and cytokine expression in 
monocytes, thus directing T cell differentiation and balancing immune clearance and 
immune injury during chronic viral infection.
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Fig. 1. miR146a is up-regulated in monocytes from chronically HCV-infected individuals
CD14+ Monocytes were purified from PBMCs from 12 HCV-infected subjects, 5 HCV SVR 
subjects following anti-viral treatment and 4 HS, stimulated with or without the TLR ligands 
LPS and R848 for 6 h, followed by real-time RT-PCR analysis of miR146a levels. (A) 
miR146a fold-changes (2−ΔΔCt) from HCV patients and SVR individuals relative to HS, 
without and with TLR stimulation, are shown. Each symbol represents one individual. 
Horizontal bar represents the median value. *P<0.05; **P<0.01, analyzed by Mann-Whitney 
test. (B) miR146a expression in monocytes from HCV patients versus HS following 
stimulation by LPS and R848 for indicated times. Error bars are shown from repeated 
experiments from multiple subjects. *P<0.05; **P<0.01, analyzed by independent t test. (C–
E) Relative miR146a expression level, normalized by U6 (2−ΔCt), in monocytes from SVR, 
HS, and HCV subjects before and after TLR stimulation. The horizontal bars represent 
median values. No significant difference between these changes, analyzed by Mann-Whitney 
test.
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Fig. 2. miR146a is up-regulated in monocytes co-cultured with HCV+/− hepatocytes
Monocytes were isolated from HS (n=3) and co-cultured with HCV+ or HCV- hepatocytes, 
followed by real-time RT-PCR analysis of miR146a expression. (A–B) Relative changes in 
miR146a levels, normalized to U6 (2−ΔCt), in monocytes co-cultured with HCV+ 
hepatocytes versus HCV- hepatocytes with or without LPS and R848 stimulations for the 
indicated times. *P<0.05, analyzed by independent t test. (C–D) Relative changes in 
miR146a level, normalized to U6 (2−ΔCt), in monocytes co-cultured with HCV+ Huh 7 or 
HCV− Huh 7 hepatocytes, respectively, after stimulation with LPS and R848. The horizontal 
bars represent median values. No significant difference between these changes, analyzed by 
Mann-Whitney test.
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Fig. 3. Effect of miR146a inhibition on inflammatory cytokine production by monocytes from 
chronically HCV-infected individuals and HS
CD14+ monocytes isolated from chronically HCV-infected individuals and HS were 
transfected with miR146a specific inhibitor or negative control for 24h, and then stimulated 
with LPS/R848 for 6h prior to harvest. Levels of IL-12 (A), IL-23 (B), IL -10 (C), and TGF-
β (D) cytokine production in the culture supernatants was measured by ELISA. Each 
symbol represents one subject. Data from the same subject, where cells were treated with 
negative control or miR146a inhibitor, are connected by a dished-line. Horizontal bars 
represent the mean value. *P<0.05; ***P<0.001, analyzed by paired t test.
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Fig. 4. Effect of miR146a inhibition on the expression of SOCS1, STAT3 and STAT1 in 
monocytes from chronically HCV-infected individuals and HS
(A) Representative Western blots showing the protein levels of SOCS1, STAT3, and STAT1 
in CD14+ monocytes from HCV-infected subjects as well as HS transfected with control (1) 
or miR146a specific inhibitor (2) for 24 h and 48 h and then stimulated with LPS/R848 for 6 
h prior to harvest. Membranes were stripped and re-probed for β-actin as a loading control. 
(B–D) Densitometric analysis of the band intensities shown in A after normalization to β-
actin levels. Images were captured and analyzed by Chemi DocTM MP Imaging System. 
Data are presented as mean ± SD. *P<0.05, analyzed by independent t test.
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Fig. 5. Effect of miR146a inhibition in monocytes from HCV-infected individuals on Foxp3+ T-
reg cell development
(A) CD14+ monocytes isolated from chronically HCV-infected individuals and HS were 
transfected with miR146a inhibitor or negative control then co-cultured with autologous 
CD14- PBMCs for 5 days, followed by flow cytometric analysis of CD4+CD25+ Foxp3+ T-
reg frequencies. Representative dot plots for the gating of CD4+ cells, and then 
CD25+Foxp3+ T cells, in the experimental and control group are shown above; and 
summary data from 14 HCV-infected patients and 6 HS are shown. Each symbol represents 
one particular subject. Data from the same subject, where cells were treated with negative 
control and miR146a inhibitor, are connected by a dished-line. Horizontal bar represents the 
mean value. **P<0.01, analyzed by paired t test. (B) Proposed model for HCV-induced, NF-
κB-mediated miR146a induction and its role in regulating cytokine production and T-regs 
development during viral infection. HCV infection induces NF-κB activation and miR146a 
expression in monocytes, which in turn induces inflammatory cytokine (e.g., IL-23, IL-10, 
TGF-β) and thus promotes Foxp3+ T-reg differentiation. miR146a may regulate TLR and 
cytokine signaling through a negative feedback loop involving SOCS1 and STAT3 signaling 
pathway during chronic viral infection.
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